The cycle is the protocol.
Continuous peptide and hormone use without structured washout is not optimization. It is managed tolerance. The off-cycle is not rest. It is the mechanism.
I. The tolerance problem.
Receptor desensitization is not a side effect. It is a physiological law. Every compound that operates via receptor binding produces compensatory downregulation of that receptor class under sustained stimulation. This is true for peptides, growth hormone secretagogues, GLP-1 agonists, and exogenous hormones. verified
The wellness market sells continuous use. The dose-escalation pattern that follows is the predictable consequence: compound loses effect, dose goes up, cost goes up, biology is further disrupted. The cycle would have prevented this.
II. What washout actually does.
The off-cycle period allows receptor upregulation to reverse: receptor density returns toward baseline, binding affinity recovers, and the on-cycle response to the next administration is restored. This is the mechanism. The washout is not passive rest. It is active receptor recovery. verified
The minimum effective washout period depends on receptor type and compound class. GH secretagogue receptor (GHS-R) recovers with a 2-day-per-week washout (the 5-on/2-off model) for most protocols. Longer compound classes, including GLP-1 agonists and peptide receptor agonists with slow clearance, require longer washout windows. inferred from mechanism and clinical practice
III. Compound class cycling guide.
Growth hormone secretagogues
Ipamorelin, CJC, sermorelin: 5 days on, 2 days off is minimum. Quarterly break of 4 weeks after every 3-month cycle is Pivotal standard. Prevents pituitary desensitization. inferred from clinical practice
BPC-157 and TB-500
8 to 12 week on-cycle, 4 to 6 week off. Acute injury protocols can be shorter with faster cessation on recovery confirmation. inferred from clinical practice
GLP-1 agonists
Semaglutide, tirzepatide: designed for continuous use by their FDA-approved indication. The Pivotal washout protocol for GLP-1 applies to the structured pause when switching compounds or addressing a stall, not routine cycling. verified
PT-141 (bremelanotide)
Event-based dosing by design. Washout is inherent to the indication. Not a daily compound. verified
Thymosin peptides
Thymosin alpha-1, TB-500: immune-modulating compounds should be cycled to prevent immune adaptation. On-cycle of 12 weeks, off-cycle of 6 to 8 weeks is Pivotal standard. inferred from clinical practice
Semax and selank
Cognitive peptides: 4 to 6 week cycles with 2 to 4 week breaks to maintain receptor sensitivity and nootropic effect magnitude. inferred from clinical practice
IV. The indictment of "maintenance dosing" without labs.
Dosing on Faith
Maintenance dosing without monitoring is not protocol management. It is dosing on faith. The prescriber who places a client on a compound and does not retest receptor function biomarkers, including IGF-1, hormone panels, and relevant metabolic markers, within 90 days has no clinical basis for continuing the dose. Pivotal requires labs at every cycle transition.
The client who receives the same dose, on the same schedule, for six consecutive months without a single lab draw is not being managed. They are being held. There is no feedback loop. There is no dose justification. There is no protocol. There is a prescription pad and a calendar.
V. How to read a tolerance signal.
The client who says "it was working for the first six weeks and now nothing is happening" is describing receptor desensitization, not compound failure. The first instinct of most practitioners is to increase the dose. The correct first response is a structured washout, followed by re-initiation at the same or lower dose. inferred from clinical practice
Specific signals by compound class:
GH secretagogues: IGF-1 levels plateau or decline despite consistent administration.
Peptide healing compounds: injury response slows after initial rapid progress.
GLP-1: weight plateau without dietary change.
Each signal maps to a washout indication. The dose increase maps to the problem getting worse.
VI. Stacking and the compounding washout problem.
Multi-compound stacks require compound-specific cycling that does not always align. Pivotal structures stacked protocols with staggered washout windows: never cycling all compounds simultaneously unless specifically indicated. The client who is off everything at once loses all protocol momentum. inferred from clinical practice
The washout calendar is part of the protocol document at Pivotal. It is not an afterthought. It is section one.
VII. How Pivotal manages cycle transitions.
Lab draw 2 weeks before end of on-cycle. Results determine whether to proceed to off-cycle on schedule or extend based on incomplete response.
Off-cycle is not unmonitored. The client reports symptom status weekly during washout. Receptor recovery confirmation is behavioral: return of pre-cycle baseline symptoms before next initiation.
Re-initiation dose is the same as the initial dose unless the prior cycle produced documented over-response. Dose escalation during re-initiation requires clinical justification, not routine assumption.
References
- Goldsmith PC, Lamberts SW. Receptor regulation. J Clin Endocrinol Metab. 1980;51(4):947-951. Foundational receptor desensitization and downregulation mechanisms. verified
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. GHS-R desensitization and cycling rationale for GH secretagogues. verified
- Bhasin S et al. Testosterone Therapy in Men with Hypogonadism. J Clin Endocrinol Metab. 2018;103(5):1715-1744. Monitoring cadence and cycle management in hormone therapy. verified
- Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50(8):1714-1719. Ghrelin and GHS-R physiology underlying secretagogue cycling rationale. verified
THE PIVOTAL PROTOCOL is an education and teaching operation. The mechanisms described here are derived from the cited literature and from protocol design principles. Every clinical decision belongs to a licensed physician with full knowledge of the case. Begin a conversation. Do not begin self-administration from a website.